221 results about "CARCINOMA LIVER" patented technology

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

The invention relates to an immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time, and belongs to the technical field of biological medicines. The model can be used for evaluating the infiltration degree of immune cells in a tumor in clinical practice by detecting the expression levels of 22 specific immune related genes of ahepatocellular carcinoma patient, so that the model can be used for predicting hepatocellular carcinoma tumor immune infiltration in clinical practice and improve the prediction capability of the liver cancer immunotherapy response. The model can be used for judging the postoperative overall survival risk of a patient and guiding the formulation of a postoperative treatment strategy, and the corresponding microarray chip kit can realize the standardization and convenience of detection. Meanwhile, the immune gene prognosis model provided by the invention can increase the prediction accuracy andthe clinical net income of a hepatocellular carcinoma TNM staging system on the total survival time of three years and five years after operation. As a molecular marker for objectively and accuratelyevaluating the tumor immune state and poor prognosis risk of hepatocellular carcinoma, the model can realize accurate implementation of hepatocellular carcinoma immunotherapy and accurate prognosis prediction.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

The invention provides a preparation method for a chlorella polypeptide microcapsule. The method comprises the following steps: extracting chlorella protein by using a low temperature ultrahigh pressure continuous flow cell crusher; hydrolyzing the chlorella protein with papain; filtering the hydrolyzed chlorella protein with an ultrafiltration centrifuge tube; then carrying out separation and purification by using ion exchange chromatography DEAE-52 and gel chromatography dextrangel G-25 columns; and finally utilizing complex coacervation to prepare the chlorella polypeptide microcapsule. The chlorella polypeptide microcapsule prepared in the invention has antitumor activity, e.g., the chlorella polypeptide microcapsule has inhibitory effects on in vitro growth of human hepatoma carcinoma cells HepG2 and the inhibition rate of the chlorella polypeptide microcapsule reaches 38% when concentration is 400 mu g/mL. Therefore, the chlorella polypeptide microcapsule prepared in the invention is beneficial for development and utilization of antitumor health food and medicinal products.

The invention relates to a marine bacillus and its polypeptide with antitumor activity. The strain is preserved at China Center for Type Culture Collection in Wuhan, and its preservation number is CCTCC M 2013063. A novel marine bacillus polypeptide with anti-tumor activity is obtained from a fermentation product of the strain. By means of an MTT method, the invention finds that the polypeptide has an obvious proliferation inhibition effect on human hepatoma carcinoma cell BEL-7402, human breast cancer cell MCF-7, human glioma cell U251, human non-small-cell lung cancer cell A549 and other tumor cells, has relatively small cytotoxicity on human fibroblast HFL1, and can be applied in drugs treating human liver cancer, gliomas, lung cancer and breast cancer.

The invention provides a novel immunomodulatory protein FIP-ppl derived from a fungus by applying a genetic engineering means for the first time. According to the invention, a gene which codes the protein is provided and synthesized. The protein FIP-ppl has immunomodulatory and anti-tumor effect. Experiments verify that the protein has a catalytic splitting effect on splenic lymphocyte and can add synthesis of interleukin 2; the protein has remarkable suppress proliferation and apoptosis-inducing effects of the protein on hepatoma carcinoma cell HepG2 and gastric carcinoma cell MCG823 are further verified. The protein FIP-ppl provided by the invention is lowly homological with almost found immunomodulatory proteins of fungi and is a novel immunomodulatory and anti-tumor biological preparation.

The present invention relates to a nanobody GN2 composed of a variable region of a heavy chain antibody; and the variable region of the heavy chain antibody comprises an epitope complementary region selected from a group consisting of CDR1, CDR2 and CDR3 and homologous sequences of the CDR1, CDR2 and CDR3 and a skeleton region selected from a group consisting of FR1, FR2, FR3 and FR4 and homologous sequences of the FR1, FR2, FR3 and FR4. The present invention also relates to a preparation method and an application of the nanobody GN2. The nanobody GN2 can specifically bind to hepatocarcinoma cells that highly express GPC3 protein, inhibits hepatocarcinoma cell proliferation, and is small in molecular weight, stable in structure, good in heat resistance, high in affinity, easy for storage and transportation, weak in immunogenicity to human body, also strong in tumor tissue penetrating power, liable to express and genetically engineered, and particularly suitable for use as a diagnosticreagent or a therapeutic antibody. The method can retain more antigen epitopes, and is high in carrier quality, good in an enzyme digestion effect, high in connection efficiency, low in self-connection efficiency and also low in cost.

The invention discloses a replicative HBV (Hepatitis B Virus) vector carrying a foreign gene and a recombinant HBV generated after transfection and a corresponding preparation method and an application. The vector separates overlaying genes C and P on an HBV genome by a molecular cloning technique based on originally expressed HBV plasmid to respectively form an integral opened reading frame where a protein translation starting sequence or a protease enzyme cutting site is inserted to respectively guide expression of foreign gene and gene P. The replicative HBV vector carrying the foreign gene transiently transfecting hepatoma carcinoma cell secretes the recombinant HBV. The recombinant HBV prepared from the HBV vector transfection cells provided by the invention can express the foreign gene and maintain the replicative and infecting capacity. The invention is suitable for constructing an HBV chronic infection animal model, an HBV cell model with cccDNA stably and automatically replicated and a traceable HBV strain, researching a molecular mechanism of HBV infection, replication, packaging and the like, and screening anti-HBV novel medicines.

The invention discloses a system used for predicting prognosis of a liver cancer patient. The system comprises a system for detecting expression quantities of four proteins c-Met, Caspase8, CXCR4 andP-P21, and a protein expression quantity data processing system. The system for detecting the expression quantities of the four proteins measures the expression quantities of the proteins through an immunohistochemistry staining method; and the protein expression quantity data processing system converts the expression quantities of the four proteins in a para-carcinoma tissue of the to-be-predicted liver cancer patient into prognosis score values, and predicts the prognosis of the liver cancer patient according to the prognosis score values.

The invention relates to a Chinese medicine for treating primary carcinoma of the liver. By the Chinese medicine, the problems about preparation of a medicament for treating primary carcinoma of the liver, improvement on curative effects and treatment for primary carcinoma of the liver are effectively solved. The technical scheme for solving the problems is that: the Chinese medicine is prepared by mixing raw materials such as 10 to 30g of musk, 25 to 50g of bezoar, 30 to 60g of thunberg fritillary bulb, 30 to 60g of pangolin, 20 to 50g of ginseng, 25 to 60g of American ginseng, 35 to 55g of notoginseng root and 30 to 60g of rhizome corydalis and grinding into powder and can be prepared into capsules or powder or pills by the conventional method. The Chinese medicine has a scientific and reasonable formula, and is easy to prepare, low in cost, good in curative effects and convenient to take, and is an innovation in medicines.

The invention discloses a chromone skeleton-containing polycyclic compound as well as a preparation method and application thereof. The preparation method comprises the following steps: with 3-iodochromone compounds and norbornene as building blocks and palladium acetate as a catalyst, carrying out a [2 + 2 + 1] domino cycloaddition reaction with benzyl bromide compounds in an organic solvent to obtain a series of polycyclic compounds containing chromone skeletons, wherein diastereostereoselective change of the product is realized by adjusting the solvent. The chromone skeleton-containing polycyclic compound contains a chromone skeleton with potential biological activity, can provide a compound source for biological activity screening, and has important application value for drug screeningand pharmaceutical industry. Meanwhile, tumor growth inhibition activity screening is carried out on human non-small cell lung cancer cells (A549) and human hepatoma carcinoma cells (HepG2) of two tumor cell strains by the compound, and the compound is found to have certain tumor cell growth inhibition activity and can be applied to preparation of anti-tumor drugs.

The invention discloses compounds represented by a general formula (I) shown in the description, wherein in the formula (I), A and B are respectively a six-membered cyclic compound containing D1, D2,D3 and D4 and a six-membered cyclic compound containing D5, D6, D7 and D8. The invention also disclose an indoleamine-2,3-dioxygenase and/or tryptophan-2,3-dioxygenase inhibitor containing the above compounds and the application of the compounds in preparation of medicaments for treating cancers. The compounds provided by the invention can effectively inhibit cell proliferation, and have good therapeutic effects on various diseases such as the cancers, significant therapeutic effects on breast cancer, cervical cancer, colon cancer, lung cancer, stomach cancer, rectal cancer, pancreatic cancer,brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, ovarian tumors, peritoneal tumors, stage IV melanoma, glioma, neuroblastoma, hepatocellular carcinoma, mastoid renal tumors, head and neck tumors, leukemia, lymphoma, myeloma and non-small cell lung cancers, and very broad application prospects.

The present invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of gastrointestinal cancers (e.g., colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, cancer of the gall bladder and/or bile ducts (e.g., cholangiocarcinoma)) in biological samples (e.g., tissue samples, stool samples, blood samples, plasma samples, cell samples, gall samples, bile samples, serum samples).

The invention relates to an antitumor application of penicillium enol A2 from penicillium citrinum. Penicillium citrinum IBPT-5 is preserved at the China Center for Type Culture Collection on December 25, 2013; the address is Wuhan University; and the preservation number is CCTCC NO:M 2013713. An experiment proves that the compound has relatively good antitumor activity on a plurality of tumor cells, and can be used for preparing cell proliferation inhibition drugs or antitumor drugs to carry out antitumor research; and the tumor cells comprise human colon cancer cells SW620, human hepatoma carcinoma cells Huh7, human colon cancer cells SW480, human esophageal squamous cancer cells KYSE450, human esophageal carcinoma cells EC9706 and human hepatoma cells PLC.